Business Context and Reporting Period
Company: Kimberly-Clark Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2006
Business Overview: The Corporation operates four global business segments: Personal Care, Consumer Tissue, K-C Professional & Other, and Health Care. The quarter was characterized by inflationary pressures, difficult price competition, and significant charges related to strategic cost reduction initiatives.
Key Financial Metrics
| Metric (Millions, except per share) | Q1 2006 | Q1 2005 |
|---|---|---|
| Net Sales | $4,067.9 | $3,905.8 |
| Gross Profit | $1,153.1 | $1,306.6 |
| Operating Profit | $420.4 | $637.6 |
| Net Income | $275.1 | $450.1 |
| Diluted EPS | $0.60 | $0.93 |
| Cash Provided by Operations | $518.9 | $608.4 |
| Total Debt (Short + Long Term) | $3,768.6 | $3,817.2 |
| Cash and Cash Equivalents | $389.2 | $833.5 |
Note: Total Debt calculated as Debt payable within one year ($1,198.2M) plus Long-Term Debt ($2,570.4M) as of March 31, 2006.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 4.2% year-over-year, driven by a 4% increase in sales volumes and a 1% improvement in net selling prices. This growth was partially offset by unfavorable currency effects of approximately 1%.
- Profit Decline: Operating profit decreased 34.1% ($217.2 million) and Net Income decreased 38.9% ($175.0 million). The primary driver was $208.6 million in pretax charges for "Competitive Improvement Initiatives" (strategic cost reductions), including workforce reductions and facility closures.
- Cost Inflation: The company faced approximately $90 million in cost inflation, driven by raw materials (polymers, superabsorbents), energy, and distribution costs.
- Accounting Change: Effective January 1, 2006, the company adopted SFAS No. 123R (Share-Based Payment), resulting in a net charge of $4.7 million to income before taxes.
- Segment Performance:
- Personal Care: Sales up 6.0%; Operating profit down 3.7% due to raw material inflation and lower selling prices.
- Consumer Tissue: Sales up 3.8%; Operating profit up 2.9% due to price increases and volume growth.
- Health Care: Sales up 5.0%; Operating profit down 7.4% due to material costs and currency impacts.
Guidance, Outlook, and Risks
- Cost Reduction Outlook: The "Competitive Improvement Initiatives" are expected to result in cumulative pretax charges of $1.0 to $1.1 billion through 2008. The company expects to achieve at least $100 million in savings in 2006 (up from a previous target of $80-$100 million) and annual pretax savings of at least $350 million by 2009.
- Capital Allocation: Full-year capital spending target remains $900 million to $1.0 billion. The company targets $750 million in share repurchases for the year; $135 million was spent in Q1.
- Inflation Risks: Management expects inflation in 2006 to be greater than originally planned, primarily due to fiber and oil costs. They intend to offset this with aggressive cost reduction actions.
- Environmental: The company is a potentially responsible party at various waste disposal sites, though management does not believe these will have a material adverse effect.
- Forward-Looking Statements: Results depend on achieving cost savings, volume increases, and stable raw material prices, all of which are subject to market volatility.
- Strategic Cost Reductions: Verify the progress of the $1.0-$1.1 billion cost reduction program and the realization of the targeted $350 million annual savings by 2009.
- Raw Material Costs: Monitor trends in fiber, polymer, and energy prices, as these significantly impact gross margins.
- Currency Exposure: Assess the impact of foreign currency fluctuations, particularly the Euro, Brazilian Real, and South Korean Won, on reported sales and earnings.
- Share Repurchases: Track the execution of the $750 million annual share repurchase program against market conditions.
- Synthetic Fuel Partnerships: Review the phase-out status of tax credits related to synthetic fuel production, which impacts the effective tax rate.